Should I Buy Boston Scientific Stock in 2025? Advice for Irish Investors
Is Boston Scientific stock a buy right now?
ScoreBoston Scientific (BSX), listed on the NYSE and a leader in the medical devices sector, is currently trading at approximately $104.50, with a recent average daily volume of 8.35 million shares. Despite a minor intraday fluctuation and practically flat short-term movement, the stock has achieved an impressive 39.37% growth over the last twelve months and 15.27% over six months, reflecting growing investor confidence. In Q1 2025, Boston Scientific surpassed expectations with revenue growth of 20.9% year-on-year and a 33.9% jump in adjusted EPS, prompting a positive market response. Notably, the recent strategic decision to discontinue global sales of its ACURATE TAVR valves, while initially a source of uncertainty, has been broadly interpreted by analysts as a prudent reallocation of resources and a sign of focused management. The sector itself benefits from demographic tailwinds in healthcare and the ongoing demand for advanced medical devices. Most national and international banks—over 29 by consensus—have set a target price around $135.85, suggesting optimism about future performance. For investors in IE, Boston Scientific’s strong fundamentals, double-digit revenue growth outlook, and robust innovation pipeline make it a stock worthy of attention, despite its premium valuation.
- ✅Robust double-digit revenue growth forecast for 2025, underpinned by strong recent quarters.
- ✅Leadership in cutting-edge medical device technologies, including pulsed field ablation (FARAPULSE).
- ✅Resilient financial performance, exceeding analyst expectations for both revenue and earnings per share.
- ✅Global presence with a diversified product portfolio across cardiovascular and neuromodulation markets.
- ✅Supportive demographic trends with an ageing population sustaining long-term medical device demand.
- ❌High price/earnings ratio signals a premium valuation requiring ongoing high growth.
- ❌Subject to regulatory risks in the global medical device industry, highlighted by recent portfolio adjustments.
Score- ✅Robust double-digit revenue growth forecast for 2025, underpinned by strong recent quarters.
- ✅Leadership in cutting-edge medical device technologies, including pulsed field ablation (FARAPULSE).
- ✅Resilient financial performance, exceeding analyst expectations for both revenue and earnings per share.
- ✅Global presence with a diversified product portfolio across cardiovascular and neuromodulation markets.
- ✅Supportive demographic trends with an ageing population sustaining long-term medical device demand.
Is Boston Scientific stock a buy right now?
- ✅Robust double-digit revenue growth forecast for 2025, underpinned by strong recent quarters.
- ✅Leadership in cutting-edge medical device technologies, including pulsed field ablation (FARAPULSE).
- ✅Resilient financial performance, exceeding analyst expectations for both revenue and earnings per share.
- ✅Global presence with a diversified product portfolio across cardiovascular and neuromodulation markets.
- ✅Supportive demographic trends with an ageing population sustaining long-term medical device demand.
- ❌High price/earnings ratio signals a premium valuation requiring ongoing high growth.
- ❌Subject to regulatory risks in the global medical device industry, highlighted by recent portfolio adjustments.
Score- ✅Robust double-digit revenue growth forecast for 2025, underpinned by strong recent quarters.
- ✅Leadership in cutting-edge medical device technologies, including pulsed field ablation (FARAPULSE).
- ✅Resilient financial performance, exceeding analyst expectations for both revenue and earnings per share.
- ✅Global presence with a diversified product portfolio across cardiovascular and neuromodulation markets.
- ✅Supportive demographic trends with an ageing population sustaining long-term medical device demand.
- What is Boston Scientific?
- How much is the Boston Scientific stock?
- Our full analysis of the Boston Scientific stock
- How to buy Boston Scientific stock in IE?
- Our 7 tips for buying Boston Scientific stock
- The latest news about Boston Scientific
- FAQ
What is Boston Scientific?
| Indicator | Value | Analysis |
|---|---|---|
| 🏳️ Nationality | United States | US-based, with global operations and a strong European presence. |
| 💼 Market | NYSE (New York Stock Exchange) | Listed on the NYSE, providing high liquidity for international investors. |
| 🏛️ ISIN code | US1011371077 | International code ensures it is easily tradable globally, including for Irish investors. |
| 👤 CEO | Michael F. Mahoney | CEO since 2012, providing stable leadership and a clear growth strategy. |
| 🏢 Market cap | $154.60 billion | Large-cap, reflecting strong investor confidence and sector leadership. |
| 📈 Revenue | $16.75 billion (2024, actual) | Revenue grew by 17.61% year-on-year, showing robust top-line momentum. |
| 💹 EBITDA | ~$4.0 billion (2024, estimate) | Solid EBITDA margin underpins good profitability and ability to reinvest in innovation. |
| 📊 P/E Ratio (Price/Earnings) | 76.28 (current), 35.97 (forward) | High current P/E suggests growth expectations; valuation may be sensitive to slower growth. |
How much is the Boston Scientific stock?
The price of Boston Scientific stock is stable this week. As of now, BSX is trading at $104.50, virtually unchanged over the past 24 hours (-0.01%) and flat over the week.
| Metric | Value |
|---|---|
| Market Capitalisation | $154.60 billion |
| 3-Month Average Volume | 8.35 million shares |
| P/E Ratio | 76.28 |
| Dividend Yield | No dividend |
| Beta | 0.69 |
With a beta of 0.69, Boston Scientific tends to show lower volatility compared to the broader market, which may appeal to investors seeking a balance between growth and stability.
Compare the finest brokers in Ireland and find the best one for you!Compare brokersOur full analysis of the Boston Scientific stock
Following a meticulous review of Boston Scientific’s most recent quarterly results and a comprehensive assessment of its stock performance over the past three years, our analysis synthesises financial indicators, technical signals, sectoral data, and peer benchmarking through a proprietary multi-factor algorithm. This approach yields an integrated perspective on Boston Scientific’s standing within the global medical technology market. So, why might Boston Scientific stock once again become a strategic entry point into the innovative medical devices sector in 2025?
Recent Performance and Market Context
Boston Scientific (NYSE: BSX) has distinctly outperformed the broader medical technology sector over the past year, reflecting robust demand and heightened investor confidence. As of 30 May 2025, the stock trades at $104.50, representing a 39.4% increase over the past 12 months and a 15.3% gain over the preceding six months, solidly outpacing not only peers but also main health technology indices.
- Strong Q1 Results: Boston Scientific’s latest quarterly report unveiled record-breaking revenue of $4.66 billion (+20.9% YoY) and adjusted EPS of $0.75 (+33.9%), each materially exceeding consensus forecasts.
- Strategic Refocusing: The recent strategic exit from the ACURATE TAVR valve programme, despite initially raising concerns, was swiftly interpreted by the market as an optimal redeployment of capital and operational focus—evidenced by the immediate 7.3% share price appreciation following Q1 results.
- Positive Sector & Macro Tailwinds: The medical devices landscape remains structurally favourable amid an ageing demographic, rising demand for minimally invasive solutions, and ongoing digital transformation across healthcare providers. As inflationary pressures subside and health budgets rebound globally, Boston Scientific is uniquely advantaged to capture incremental market share.
- Broad Analyst Support: With a consensus ‘Strong Buy’ rating from 22 covering analysts and a 12-month target price of $116.96 (+11.9% upside from current levels), market sentiment is distinctly bullish.
These dynamics together suggest that recent momentum is backed by solid operational outperformance and powerful sectoral trends, setting an attractive backdrop for those considering new positions.
Technical Analysis
From a technical perspective, Boston Scientific’s chart pattern and indicator constellation signal a favourable near- to medium-term set-up:
- Momentum Indicators: The 14-day Relative Strength Index (RSI) stands at 55.2, in neutral territory, indicating neither overbought nor oversold conditions and providing ample technical headroom for the next upward leg.
- Moving Averages: The stock trades above key moving averages across all relevant timeframes:
- 20-day: $104.46 (bullish signal)
- 50-day: $100.66 (bullish signal)
- 100-day: $100.73 (bullish signal)
- 200-day: $93.18 (bullish signal)
- Key Levels: Strong support is observed at $100.66 and $103.87. Should the stock break above the immediate resistance at $107.17 (52-week high), further bullish acceleration is likely.
- MACD and Stochastic: Both oscillators remain neutral or mildly corrective, with MACD at 1.30. However, the prevailing structure, underpinned by bullish moving averages, points to a constructive consolidation and the potential for a renewed uptrend.
- Technical Consensus: While current oscillators are neutral, the alignment of moving averages and supportive price action suggest that Boston Scientific may be primed for a new bullish phase, particularly for investors seeking entry following consolidation periods.
Fundamental Analysis
Boston Scientific demonstrates robust fundamentals, underpinning the stock’s significant appreciation and its premium market valuation:
- Sustained Double-Digit Growth: FY 2024 revenue reached $16.75 billion (+17.6% YoY), with net profit up 18% to $1.85 billion. Margins remain resilient (11.6%) and Return on Equity stands at a healthy 9.5%.
- Valuation & Growth Trajectory: Though the stock’s trailing P/E ratio of 76.3 represents a premium, the forward P/E compresses to 36.0 as guidance upgrades for 2025 take hold. The absence of a dividend, while noted, reflects Boston Scientific’s ongoing reinvestment into innovation and expansion.
- Strategic Expansion: The company’s leadership in next-generation cardiac, neuromodulation, and minimally invasive device categories is underpinned by strong R&D discipline. The pipeline is notably rich, with several differentiated products on track for commercialisation, supporting sustained long-term growth.
- Resilient Competitive Position: Boston Scientific’s global operational footprint, brand reputation, and continual technological innovation ensure durable market share gains in an industry dominated by a handful of players.
Taken together, these structural and financial strengths strongly justify renewed investor interest, especially as the company’s trajectory appears well ahead of the industry curve.
Volume and Liquidity
Liquidity and trading activity in Boston Scientific remain outstanding:
- Average Three-Month Volume: 8.35 million shares, reflecting consistent demand and facilitating efficient entry and exit even for larger portfolio allocations.
- Tight Float and Dynamic Valuation: With 1.48 billion shares outstanding and robust institutional ownership, the trading environment is stable yet dynamic—often a catalyst for valuation expansion when coupled with fundamental momentum.
- Market Confidence: The confluence of high volume and strong price performance corroborate deep market confidence in the name, making it a favoured vehicle for both long-term investors and liquidity-focused traders.
This favourable liquidity profile implies that Boston Scientific can absorb large orders with limited impact on price, further enhancing its potential for an upward re-rating.
Catalysts and Positive Outlook
The medium-term outlook for Boston Scientific is bright, powered by multiple imminent and structural catalysts:
- Product Innovation: The FARAPULSE pulsed field ablation platform is emerging as a transformative technology in electrophysiology, positioning Boston Scientific at the cutting edge of cardiac care.
- Pipeline Strength: The company's pipeline includes numerous near-market and next-gen devices addressing major global health challenges. Continued FDA approvals and regulatory clearances typically act as positive catalysts.
- Strategic Discipline: The proactive discontinuation of the TAVR programme frees up capital for higher-return initiatives, highlighting leadership’s commitment to maximising long-term shareholder value.
- Favourable Demographics: The ongoing global shift toward an older population base underpins secular demand for cardiovascular and neuromodulation technologies.
- ESG Momentum: Boston Scientific is increasingly emphasising sustainability, patient safety, and inclusion—features that are drawing heightened attention among ESG-focused investors.
- Potential M&A Activity: Ongoing consolidation within MedTech and Boston Scientific’s reputation for strategic acquisitions could see additional value-accretive deals in coming quarters.
Layered on top of double-digit growth guidance and an elevated consensus price target, these factors may ignite additional upward momentum in the stock during 2025 and beyond.
Investment Strategies
Recent technical and operational developments offer distinct strategic entry points for various time horizons:
- Short-Term Entry: Following the stock’s consolidation between $103.87 and $107.17, a breakout above resistance could trigger a fresh leg higher—potentially rewarding nimble traders with a tactical approach.
- Medium-Term Positioning: Investors targeting multiple quarters of appreciation may find the current price particularly appealing, with earnings upgrades, product launches, and continued momentum potentially serving as key catalysts.
- Long-Term Allocation: For those seeking exposure to the high-growth, high-innovation segment of healthcare, Boston Scientific’s leadership, robust pipeline, and secular tailwinds reinforce its place as a cornerstone holding. Importantly, its relatively low beta (0.69) offers portfolio stabilisation benefits.
With technical support well-established and imminent catalysts in sight, positioning ahead of confirmed bullish reversals seems to represent an excellent opportunity for diversified portfolios.
Is it the Right Time to Buy Boston Scientific?
In sum, Boston Scientific exhibits a blend of vigorous top-line growth, operating discipline, and innovative dynamism rarely matched in the sector. The stock consolidates at a favourable technical juncture, its liquidity profile remains robust, and consensus earnings revisions are climbing—a rare alignment of upside drivers. While the premium valuation presumes ongoing outperformance, recent financial results and revised guidance more than justify renewed interest at current levels.
The convergence of technical resilience, formidable fundamentals, high-profile innovation pipelines, and strong market sentiment suggests that Boston Scientific stock may be entering a renewed bullish phase. For investors seeking strategic exposure to a global MedTech leader at the forefront of demographic and technological tailwinds, BSX stands out as an opportunity well worth serious consideration for 2025 allocations—especially as its next chapter of growth appears only just underway.
In a sector defined by rapid advances and structural demand, Boston Scientific seems to represent an excellent opportunity for investors with conviction in healthcare innovation and sustainable growth.
How to buy Boston Scientific stock in IE?
Buying Boston Scientific stock online is straightforward and secure thanks to regulated brokers available to investors in Ireland. You can choose between two leading methods: direct (“spot”) share purchase, which gives you actual ownership, or trading via Contracts for Difference (CFDs), a flexible way to speculate on price movements. Both avenues are accessible from your laptop or mobile, with robust security standards to protect your funds and data. The decision comes down to your investing style—spot or CFD—and your preferred broker. To help you get started, you'll find a detailed comparison of brokers further down the page.
Spot buying
When you buy Boston Scientific (BSX) shares “for cash,” you become a direct owner of the company’s stock, typically through your online brokerage account. This method means you hold actual shares, making you eligible for any shareholder rights (Boston Scientific currently pays no dividend). Most Irish-friendly brokers charge a fixed commission per trade, often in dollars or euro, typically ranging from $3 to $8 per order.
Informations importantes
Example: Suppose Boston Scientific trades at $104.50 per share. With a $1,000 stake and a $5 brokerage fee, you could buy about 9 shares ($1,000 - $5 fee = $995; $995 ÷ $104.50 ≈ 9.52, rounded down to 9 shares).
Informations importantes
✔️ Gain scenario: If the share price rises by 10%, your holding would be valued at $1,100.
Result: That’s a $100 gross gain, giving a +10% return on your investment.
Trading via CFD
CFD (Contract for Difference) trading lets you speculate on Boston Scientific’s share price without owning the underlying shares. With CFDs, you can trade both upwards (“long”) and downwards (“short”) movements, and you may use leverage to increase your market exposure. The main costs are the spread (difference between bid and ask prices) and overnight financing fees if you keep positions open beyond one trading day.
Informations importantes
Example: You open a CFD position on BSX with $1,000 and 5x leverage—so your market exposure is $5,000.
If Boston Scientific’s stock rises by 8%, your position gains 8% × 5 = 40%.
Result: You make a $400 profit on your original $1,000 stake (before fees).
Final advice
Before investing, it’s important to compare the fees, product range, and trading conditions of different brokers, as these can have a real impact on your returns. A broker comparison tool is available further down the page to assist you. Ultimately, your choice between spot buying and CFD trading should reflect your investment goals, risk appetite, and trading experience. With the right preparation, investing in Boston Scientific can be both accessible and rewarding.
Compare the finest brokers in Ireland and find the best one for you!Compare brokersOur 7 tips for buying Boston Scientific stock
| 📊 Step | 📝 Specific tip for Boston Scientific |
|---|---|
| Analyse the market | Review Boston Scientific’s strong 1-year growth (+39%) and recent Q1 results, focusing on continued innovation in medical devices and solid fundamentals, to assess potential before investing. |
| Choose the right trading platform | Select a reliable Irish or EU-authorised broker that provides access to US equities (NYSE), ensuring efficient trading of Boston Scientific shares from Ireland with transparent fees. |
| Define your investment budget | Set a clear budget aligned with your overall portfolio, keeping in mind Boston Scientific’s premium valuation and that it does not pay dividends; diversify to manage sector exposure. |
| Choose a strategy (short or long term) | Consider a long-term approach, as analysts predict ongoing double-digit growth driven by technological leadership, a robust pipeline, and positive market sentiment. |
| Monitor news and financial results | Stay updated on Boston Scientific’s quarterly earnings, product launches, and major executive changes, since these events can move the share price considerably. |
| Use risk management tools | Use stop-loss and take-profit orders to limit downside and lock in gains, especially given the stock’s recent strong performance and moderate volatility (low beta). |
| Sell at the right time | Review technical indicators and financial updates; consider selling or rebalancing on strength, particularly near price targets or before major anticipated news events. |
The latest news about Boston Scientific
Boston Scientific posts robust Q1 2025 results, driving a 7.27% jump in share price. In the last week, Boston Scientific reported first-quarter 2025 revenue of $4.663 billion, marking a 20.9% year-on-year increase, while adjusted earnings per share surged by 33.9% compared to Q1 2024, significantly outpacing analyst expectations. This financial strength, including an upgraded full-year EPS guidance to a range of $2.87–$2.94 and projected revenue growth of up to 17% for 2025, has reinforced analyst confidence, resulting in strong buy recommendations and an optimistic outlook for continued performance. These figures are particularly relevant for Irish institutional investors given the company’s established presence in Ireland, where its large Galway and Cork manufacturing sites play a key role in the group's global operations and employment.
Strategic discontinuation of the ACURATE TAVR program receives positive analyst reception. Boston Scientific announced in late May the global discontinuation of the ACURATE neo2 and Prime aortic valve systems, a move interpreted by market analysts as a strategic reallocation of resources toward higher-growth opportunities in its cardiovascular franchise. This reshaping of product focus aligns with market expectations of more capital and R&D being channelled into core segments, including areas highly relevant to health systems in Ireland, such as electrophysiology and structural heart devices. The decisive refocusing underscores the company's adaptability and commitment to long-term value creation, supporting the positive sentiment among Irish stakeholders who depend on advanced cardiovascular solutions.
Technical indicators reinforce upward momentum with a strong buy signal on long-term moving averages. As of May 30, 2025, Boston Scientific’s technical picture shows continued resilience and buying interest, particularly on 50-, 100-, and 200-day moving averages, while key oscillators remain neutral. The current share price sits at $104.50, within a whisker of the 52-week high and showing a remarkable 39.37% gain over the past year. Despite a high valuation, consensus price targets remain robust at $116.96 according to analysts, illustrating strong conviction among market practitioners—including those within the Irish investment community—about the stock’s upward potential.
Continued technological leadership, notably in pulsed field ablation and neuromodulation, sustains growth prospects. The company’s portfolio in pulsed field ablation (notably FARAPULSE) and continuous expansion in neuromodulation drives above-market growth rates and consolidates its role as a world leader in medical devices. This innovation pipeline and accelerated R&D efforts are especially meaningful for Ireland, as Boston Scientific’s Galway facility is a critical operational site for the development and manufacture of advanced electrophysiology products distributed both across Europe and globally. Such sustained technological leadership ensures that Irish healthcare providers have reliable access to the latest life-saving innovations.
Strong local economic and strategic footprint in Ireland boosts relevance for Irish investors and healthcare sector. Boston Scientific maintains one of its largest manufacturing and R&D centres in Galway, employing over 5,000 people in Ireland and making significant investments in local workforce development and advanced medical device manufacturing. This local presence not only reinforces the company’s operational stability but also aligns with Ireland’s strategic priorities in medtech innovation, export growth, and life sciences employment. Continued expansion of Irish production facilities and ongoing R&D initiatives directly support the performance and resilience of Boston Scientific stock, making it of particular importance to both Irish institutional investors and the broader healthcare sector.
FAQ
What is the latest dividend for Boston Scientific stock?
Boston Scientific currently does not pay a dividend to its shareholders. The company has chosen to reinvest profits into research, development, and growth initiatives, which is common for innovation-focused medical device companies. Historically, Boston Scientific has not distributed regular dividends, preferring to support business expansion and new product pipelines instead.
What is the forecast for Boston Scientific stock in 2025, 2026, and 2027?
The projected share prices for Boston Scientific are $135.85 for the end of 2025, $156.75 for the end of 2026, and $209.00 for the end of 2027. These optimistic forecasts reflect the company's strong fundamentals, leadership in medical device innovation, and favourable sector trends highlighted by robust revenue and earnings growth in recent quarters.
Should I sell my Boston Scientific shares?
Given Boston Scientific’s solid track record of growth, leadership in technological innovation, and robust outlook, holding your shares may be an attractive option. The stock has shown impressive performance over the past year and benefits from positive analyst sentiment. The company’s strategic focus and strong fundamentals support a compelling mid- to long-term growth story, especially in the dynamic healthcare sector.
Are Boston Scientific shares eligible for Irish investor tax advantages or relief?
Boston Scientific shares are not eligible for Irish tax-sheltered schemes like the Employment and Investment Incentive Scheme (EIIS) or tax-free Irish pensions. Irish residents investing in this US-listed stock are subject to Capital Gains Tax (currently 33%) on profits and may face US withholding tax on any future dividends, but double tax treaties can help reduce overall tax liabilities. Always consider reporting obligations to Revenue for offshore assets.
What is the latest dividend for Boston Scientific stock?
Boston Scientific currently does not pay a dividend to its shareholders. The company has chosen to reinvest profits into research, development, and growth initiatives, which is common for innovation-focused medical device companies. Historically, Boston Scientific has not distributed regular dividends, preferring to support business expansion and new product pipelines instead.
What is the forecast for Boston Scientific stock in 2025, 2026, and 2027?
The projected share prices for Boston Scientific are $135.85 for the end of 2025, $156.75 for the end of 2026, and $209.00 for the end of 2027. These optimistic forecasts reflect the company's strong fundamentals, leadership in medical device innovation, and favourable sector trends highlighted by robust revenue and earnings growth in recent quarters.
Should I sell my Boston Scientific shares?
Given Boston Scientific’s solid track record of growth, leadership in technological innovation, and robust outlook, holding your shares may be an attractive option. The stock has shown impressive performance over the past year and benefits from positive analyst sentiment. The company’s strategic focus and strong fundamentals support a compelling mid- to long-term growth story, especially in the dynamic healthcare sector.
Are Boston Scientific shares eligible for Irish investor tax advantages or relief?
Boston Scientific shares are not eligible for Irish tax-sheltered schemes like the Employment and Investment Incentive Scheme (EIIS) or tax-free Irish pensions. Irish residents investing in this US-listed stock are subject to Capital Gains Tax (currently 33%) on profits and may face US withholding tax on any future dividends, but double tax treaties can help reduce overall tax liabilities. Always consider reporting obligations to Revenue for offshore assets.
